A study presented at the World Diabetes Congress revealed adolescent type 1 diabetes patients who used a closed-loop continuous glucose monitoring system attained lower mean glucose levels and fewer nocturnal hypoglycemia incidents compared with those who used sensor-augmented pump therapy. Patients who used the artificial pancreas also had more time in blood glucose targets than the sensor-augmented pump arm, researchers noted.

Related Summaries